Illuminant Surgical

Executive Summary

Illuminant Surgical, founded in 2019 and headquartered in Cambridge, MA, is pioneering augmented reality guidance for surgery with its flagship product, Skylight™. This real-time anatomical projection system uses AI and computer vision to overlay medical imaging directly onto the patient's body, enhancing spatial awareness and simplifying surgical navigation. By projecting critical structures onto the surgical field, Skylight aims to reduce errors, shorten procedure times, and improve outcomes across various surgical specialties. The company operates at the intersection of medical devices and AI, targeting a market ripe for innovation in precision surgery. The company is early-stage and privately held, with no disclosed funding rounds or regulatory clearances to date. Its success hinges on obtaining FDA clearance (likely 510(k) pathway) and building clinical evidence demonstrating improved accuracy and workflow integration. Key challenges include competition from established navigation players and emerging AR/VR platforms, as well as the need to demonstrate cost-effectiveness to hospital systems. If Illuminant navigates regulatory hurdles and forms strategic partnerships, Skylight could become a standard tool in minimally invasive surgery. However, given the nascent stage, the conviction is moderate.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Skylight System60% success
• Q1 2027First Clinical Study Results Publication65% success
• Q3 2026Series A Financing Round70% success